PURPOSE: This study prospectively assessed second-look ultrasound (US) for the evaluation of incidental enhancing lesions identified on preoperative breast magnetic resonance imaging (MRI). MATERIALS AND METHODS: Between 2004 and 2007, 182 patients with malignant breast lesions detected on US and/or X-ray mammography and confirmed by cytology/histology underwent preoperative breast contrast-enhanced (CE)-MRI. Patients with incidental lesions on breast MRI underwent second-look high-resolution US directed at the site of the incidental finding. Diagnosis of incidental lesions was based on biopsy or 24-month follow-up. RESULTS: Breast MRI detected 55 additional lesions in 46/182 (25.2%) patients. Forty-two of 55 (76.3%) lesions were detected on second-look US in 38/46 (82.6%) patients. Malignancy was confirmed for 24/42 (57.1%) correlate lesions compared with 7/13 (53.8%) noncorrelate lesions. Second-look US depicted 8/9 (88.8%) Breast Imaging Reporting and Data System (BI-RADS) 5, 16/22 (72.7%) BI-RADS 4 and 18/24 (75%) BI-RADS 3 lesions. Sensitivity, specificity, accuracy and positive and negative predictive values for lesion detection/diagnosis was 100%, 88.9%, 94.6%, 90.3% and 100% for MRI and 64.3%, 70.4%, 67.3%, 69.2% and 65.5% for second-look US. Improved performance for US was obtained when masslike lesions only were considered. CONCLUSIONS: Second-look US is a confirmatory method for incidental findings on breast MRI, particularly for mass-like lesions.
PURPOSE: This study prospectively assessed second-look ultrasound (US) for the evaluation of incidental enhancing lesions identified on preoperative breast magnetic resonance imaging (MRI). MATERIALS AND METHODS: Between 2004 and 2007, 182 patients with malignant breast lesions detected on US and/or X-ray mammography and confirmed by cytology/histology underwent preoperative breast contrast-enhanced (CE)-MRI. Patients with incidental lesions on breast MRI underwent second-look high-resolution US directed at the site of the incidental finding. Diagnosis of incidental lesions was based on biopsy or 24-month follow-up. RESULTS: Breast MRI detected 55 additional lesions in 46/182 (25.2%) patients. Forty-two of 55 (76.3%) lesions were detected on second-look US in 38/46 (82.6%) patients. Malignancy was confirmed for 24/42 (57.1%) correlate lesions compared with 7/13 (53.8%) noncorrelate lesions. Second-look US depicted 8/9 (88.8%) Breast Imaging Reporting and Data System (BI-RADS) 5, 16/22 (72.7%) BI-RADS 4 and 18/24 (75%) BI-RADS 3 lesions. Sensitivity, specificity, accuracy and positive and negative predictive values for lesion detection/diagnosis was 100%, 88.9%, 94.6%, 90.3% and 100% for MRI and 64.3%, 70.4%, 67.3%, 69.2% and 65.5% for second-look US. Improved performance for US was obtained when masslike lesions only were considered. CONCLUSIONS: Second-look US is a confirmatory method for incidental findings on breast MRI, particularly for mass-like lesions.
Authors: Francesco Sardanelli; Gian M Giuseppetti; Pietro Panizza; Massimo Bazzocchi; Alfonso Fausto; Giovanni Simonetti; Vincenzo Lattanzio; Alessandro Del Maschio Journal: AJR Am J Roentgenol Date: 2004-10 Impact factor: 3.959
Authors: Federica Pediconi; Carlo Catalano; Simona Padula; Antonella Roselli; Enrica Moriconi; Valeria Dominelli; Anna Maria Pronio; Miles A Kirchin; Roberto Passariello Journal: Breast Cancer Res Treat Date: 2007-01-03 Impact factor: 4.872
Authors: C Boetes; R D Mus; R Holland; J O Barentsz; S P Strijk; T Wobbes; J H Hendriks; S H Ruys Journal: Radiology Date: 1995-12 Impact factor: 11.105
Authors: Elena Belloni; Pietro Panizza; Silvia Ravelli; Francesco De Cobelli; Simone Gusmini; Claudio Losio; Isabella Sassi; Gianluca Perseghin; Alessandro Del Maschio Journal: Radiol Med Date: 2013-06-25 Impact factor: 3.469
Authors: Ceren Yalnız; Juliana Rosenblat; David Spak; Wei Wei; Marion Scoggins; Carisa Le-Petross; Mark J Dryden; Beatriz Adrada; Başak E Doğan Journal: Eur J Breast Health Date: 2019-10-01
Authors: Michael Kolta; Paola Clauser; Panagiotis Kapetas; Maria Bernathova; Katja Pinker; Thomas H Helbich; Pascal A T Baltzer Journal: Eur J Radiol Date: 2020-04-11 Impact factor: 3.528